Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

Conditions: Gastric Cancer; HER2-positive Gastric Cancer Interventions: Drug: Experimental; Drug: Control Sponsors: Gruppo Oncologico del Nord-Ovest Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials